Jeffrey Foy
Corporate Officer/Principal bij PEPGEN INC.
Profiel
Jeffrey Foy is a member of the Oligonucleotide Therapeutics Society, Inc. and the Vice President-Toxicology at PepGen Inc. He was previously an Executive Director-Toxicology at Dicerna Pharmaceuticals, Inc. He has a graduate degree from Northeastern University and an undergraduate degree from the University of Vermont.
Actieve functies van Jeffrey Foy
| Bedrijven | Functie | Begin |
|---|---|---|
| PEPGEN INC. | Corporate Officer/Principal | - |
Oligonucleotide Therapeutics Society, Inc.
 Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The private company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | Corporate Officer/Principal | - |
Eerdere bekende functies van Jeffrey Foy
| Bedrijven | Functie | Einde |
|---|---|---|
| DICERNA PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Opleiding van Jeffrey Foy
| Northeastern University | Graduate Degree |
| University of Vermont | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| PEPGEN INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Dicerna Pharmaceuticals, Inc.
 Dicerna Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA. | Health Technology |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The private company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | Commercial Services |
